Download PDF
Research Highlight  |  Open Access  |  13 Nov 2024

Engineered extracellular vesicles as “supply vehicles” to alleviate type 1 diabetes

Views: 62 |  Downloads: 18 |  Cited:  0
Extracell Vesicles Circ Nucleic Acids 2024;5:718-21.
10.20517/evcna.2024.61 |  © The Author(s) 2024.
Author Information
Article Notes
Cite This Article

Abstract

Recent findings have indicated that the deficiency of inhibitory programmed cell death ligand 1 (PD-L1) and galectin-9 (Gal-9) in pancreatic β-cells is associated with the progression of type 1 diabetes (T1D). This suggests that exogenous PD-L1 and Gal-9 may have promising potential as therapeutics for the treatment of T1D. In light of these reports, a recent work investigated the potential of artificial extracellular vesicles (aEVs) with the presentation of PD-L1 and Gal-9 ligands (PD-L1–Gal-9 aEVs) as a treatment for T1D, with the findings published in Diabetes. Notably, the PD-L1–Gal-9 aEVs demonstrated the capacity to induce apoptosis of T cells and the formation of regulatory T (Treg) cells, thereby maintaining immune tolerance. Furthermore, the in vivo administration of PD-L1–Gal-9 aEVs resulted in a reduction in T cell infiltration in the pancreas, an increase in β-cell integrity protection, a significant decrease in blood glucose levels, and a delay in the progression of T1D. In conclusion, this study proposed an innovative approach to the treatment of T1D progression through the use of immunosuppressive EVs. This highlight provides a comprehensive analysis and discussion of the pivotal findings of this study.

Keywords

Extracellular vesicles, type 1 diabetes, PD-L1, Gal-9, hyperglycemia

MAIN TEXT

Type 1 diabetes (T1D) is an autoimmune disease that is characterized by elevated blood glucose levels. This results from T lymphocyte-caused damage to the β-cells in the pancreas and subsequent insulin secretion failure[1,2]. T1D accounts for 5%-10% of all reported diabetic cases, with a globally increasing incidence[3]. It is postulated that T1D is a highly heterogeneous disease, influenced by a variety of factors, including age, genetic alterations, and environmental influences. Research suggests that pancreatic β-cells and their interactions with immune cells play a pivotal role in the development and pathogenic progression of T1D[4]. Insulin therapy is considered the primary treatment option for T1D, as it has a crucial role in the regulation of glucose intracellular transportation[5-7]. However, insulin therapy is confronted with significant adverse effects, including hypoglycemia and insulin resistance. Considering the interactions between pancreatic β-cells and immune cells, a variety of immunosuppressive therapies have been proposed as potential alternatives for the treatment of T1D[8]. In 2022, the US Food and Drug Administration (FDA) approved teplizumab, a CD3-binding monoclonal antibody, for the prevention of T1D. Nevertheless, teplizumab therapy may result in severe side effects and is currently expensive[9]. Therefore, it is necessary to develop treatment methodologies with enhanced therapeutic effects for the prevention and treatment of T1D.

Recently, nanotechnology-based biomaterials have been employed extensively as therapeutic agents or innovative drug delivery platforms in treating a variety of illnesses, including T1D[10-13]. Among the various types of nanomaterials, extracellular vesicles (EVs), which are nano-sized phospholipid bilayer membrane-enclosed particles secreted by various cell types, have attracted considerable interest for their potential as a next-generation nanomedicine with applications in numerous biomedical fields[14-18]. In particular, it has been demonstrated that EVs derived from various cell resources, including mesenchymal stem cells (MSCs), adipocytes, and endothelial progenitor cells (EPCs), achieved remarkable therapeutic efficacy in the treatment of T1D[19]. For instance, MSC-derived exosomes have been demonstrated to stimulate the regeneration of pancreatic islet cells and insulin secretion by regulating a group of genes[20]. In addition, microvesicles derived from EPCs were shown to facilitate the neoangiogenesis process of the transplanted islet via the delivery of miRNAs[21].

It is noteworthy that EVs can be utilized as drug delivery platforms for various biomolecules, such as nucleic acids, proteins, and chemotherapeutic drugs[22-25]. For example, Wang et al. proposed an inhalable vaccine for the prevention of SARS-CoV-2[26]. The vaccine is developed using lung-derived exosomes with conjugation to the recombinant domains binding to SARS-CoV-2 receptors (RBD). The exosome vaccine was observed to improve the retention rate and time of RBD within the lung, and also inducing systemic mucosal immunity and T cell immunity in mice and hamsters[26,27]. In another report, decoy exosomes modified with GC-enriched tetrahedral DNA nanostructures have been shown to mitigate doxorubicin (DOX)-induced hepatotoxicity by scavenging DOX and polarizing macrophages into the M2 phenotype[28].

Given their remarkable capacity to carry cargo, EVs could also be employed as “supply vehicles” of therapeutic biomolecules in the treatment of T1D. A deficiency in immune checkpoint molecules with pro-inhibitory effects, including programmed cell death ligand 1 (PD-L1) and galectin-9 (Gal-9), has been observed in pancreatic β-cells and has been linked to the progression of T1D[29]. Accordingly, Yang et al. postulated that the delivery of exogenous PD-L1 and Gal-9 to β-cells might result in an immunosuppressive therapeutic effect, thereby alleviating T1D[30]. By leveraging genetic engineering technology, the authors generated Raw264.7 cells overexpressing PD-L1 and Gal-9 molecules on their cell membranes. The overexpression of Gal-9 resulted in the transformation of the Raw264.7 cells to an M2 macrophage phenotype. In addition, genetically engineered Raw264.7 cells were demonstrated to generate artificial extracellular vesicles (aEVs) with high expression levels of PD-L1 and Gal-9 (called PD-L1–Gal-9 aEVs). The developed EV-based nanoplatforms displayed the binding ability to the PD-1 and T-cell immunoglobulin mucin 3 (TIM-3) receptors on the T lymphocytes. The binding is attributed to the interactions between PD-L1 and PD-1, as well as Gal-9 and TIM-3.

The authors showed that the PD-L1–Gal-9 aEVs induced a significant inhibition of the AKT signaling pathway and the induction of T cell apoptosis. Treatment with PD-L1–Gal-9 aEVs resulted in notable expansion of the regulatory T (Treg) cell population. Furthermore, this study provided in vivo evidence of the therapeutic effects of the developed EV-based nanoplatforms. In vivo imaging results demonstrated the distribution of the developed EV-based nanoplatforms in the pancreas following intravenous administration. Moreover, the treatment with PD-L1–Gal-9 aEVs was observed to markedly attenuate T1D progression in a diabetic mouse model, accompanied by elevated levels of C-peptide and IL-10 expression. Additionally, PD-L1–Gal-9 aEVs demonstrated capacity in safeguarding pancreatic β-cells from destruction, impeding the T cell infiltration, and enhancing the population of Treg cells within the pancreatic tissue.

The study collectively presented an aEV-based platform for the delivery of therapeutic factors to pancreatic tissue, with the objective of improving T1D outcomes. The destruction of β-cells in the pancreas tissue by autoreactive T cells represents a critical cause of T1D. The authors demonstrated that the administration of immunosuppressive PD-L1 and Gal-9 represents an efficacious approach to inhibit the infiltration of T cells and alleviate T1D. This study suggested that aEVs could serve as a delivery system for macromolecules, such as proteins, for the treatment of T1D. In light of the benefits associated with aEVs, including high yield, reduced expense, and fewer side effects, aEVs are emerging as a promising therapeutic nanoplatform for the treatment of T1D.

DECLARATIONS

Authors’ contributions

Writing, reviewing, and editing the draft: Wang F, Li Z

Availability of data and materials

Not applicable.

Financial support and sponsorship

None.

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2024.

REFERENCES

1. Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol 2021;17:150-61.

2. Zhang J, Lin C, Jin S, et al. The pharmacology and therapeutic role of cannabidiol in diabetes. Exploration 2023;3:20230047.

3. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect 2020;10:98-115.

4. Li Y, Sun F, Yue TT, et al. Revisiting the antigen-presenting function of β cells in T1D pathogenesis. Front Immunol 2021;12:690783.

5. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev 2005;26:19.

6. Primavera R, Kevadiya BD, Swaminathan G, et al. Emerging nano- and micro-technologies used in the treatment of type-1 diabetes. Nanomaterials 2020;10:789.

7. Liu J, Zhou Y, Lyu Q, Yao X, Wang W. Targeted protein delivery based on stimuli-triggered nanomedicine. Exploration 2024;4:20230025.

8. Lernmark A, Larsson HE. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol 2013;9:92-103.

9. Goldman JD, Choi H. Teplizumab: the first treatment to delay the progression of type 1 diabetes. Clin Diabetes 2023;41:474-6.

10. Veiseh O, Tang BC, Whitehead KA, Anderson DG, Langer R. Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discov 2015;14:45-57.

11. Jing Z, Li Y, Ma Y, Zhang X, Liang X, Zhang X. Leverage biomaterials to modulate immunity for type 1 diabetes. Front Immunol 2022;13:997287.

12. Feng C, Tan P, Nie G, Zhu M. Biomimetic and bioinspired nano-platforms for cancer vaccine development. Exploration 2023;3:20210263.

13. Dai H, Fan Q, Wang C. Recent applications of immunomodulatory biomaterials for disease immunotherapy. Exploration 2022;2:20210157.

14. Zhang K, Cheng K. Stem cell-derived exosome versus stem cell therapy. Nat Rev Bioeng 2023;Online ahead of print.

15. Cheng K, Kalluri R. Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics. Extracellular Vesicle 2023;2:100029.

16. Li L, Wang F, Zhu D, Hu S, Cheng K, Li Z. Engineering exosomes and exosome-like nanovesicles for improving tissue targeting and retention. Fundamental Research 2024;Online ahead of print.

17. Zhu D, Cheng K. Cardiac cell therapy for heart repair: should the cells be left out? Cells 2021;10:641.

18. Ding Y, Wang Y, Hu Q. Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. Exploration 2022;2:20210106.

19. Soltani S, Mansouri K, Emami Aleagha MS, et al. Extracellular vesicle therapy for type 1 diabetes. Front Immunol 2022;13:865782.

20. Sabry D, Marzouk S, Zakaria R, Ibrahim HA, Samir M. The effect of exosomes derived from mesenchymal stem cells in the treatment of induced type 1 diabetes mellitus in rats. Biotechnol Lett 2020;42:1597-610.

21. Cantaluppi V, Biancone L, Figliolini F, et al. Microvesicles derived from endothelial progenitor cells enhance neoangiogenesis of human pancreatic islets. Cell Transplant 2012;21:1305-20.

22. Liu M, Hu S, Yan N, Popowski KD, Cheng K. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat Nanotechnol 2024;19:565-75.

23. Liu H, Zhang X, Zhang M, et al. Mesenchymal stem cell derived exosomes repair uterine injury by targeting transforming growth factor-β signaling. ACS Nano 2024;18:3509-19.

24. Popowski KD, López de Juan Abad B, George A, et al. Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung. Extracell Vesicle 2022;1:100002.

25. Zhu D, Liu S, Huang K, et al. Intrapericardial exosome therapy dampens cardiac injury via activating Foxo3. Circ Res 2022;131:e135-50.

26. Wang Z, Popowski KD, Zhu D, et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat Biomed Eng 2022;6:791-805.

27. Popowski KD, Dinh PC, George A, Lutz H, Cheng K. Exosome therapeutics for COVID-19 and respiratory viruses. View 2021;2:20200186.

28. Fan M, Li H, Shen D, et al. Decoy exosomes offer protection against chemotherapy-induced toxicity. Adv Sci 2022;9:e2203505.

29. Ding JT, Yang KP, Lin KL, Cao YK, Zou F. Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes. Front Endocrinol 2022;13:1090842.

30. Yang Z, Zhang Z, Li L, et al. Bioengineered artificial extracellular vesicles presenting PD-L1 and Gal-9 ameliorate new-onset type 1 diabetes. Diabetes 2024;73:1325-35.

Cite This Article

Research Highlight
Open Access
Engineered extracellular vesicles as “supply vehicles” to alleviate type 1 diabetes
Fei Wang, Zhenhua Li

How to Cite

Wang, F.; Li, Z. Engineered extracellular vesicles as “supply vehicles” to alleviate type 1 diabetes. Extracell. Vesicles. Circ. Nucleic. Acids. 2024, 5, 718-21. http://dx.doi.org/10.20517/evcna.2024.61

Download Citation

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click on download.

Export Citation File:

Type of Import

Tips on Downloading Citation

This feature enables you to download the bibliographic information (also called citation data, header data, or metadata) for the articles on our site.

Citation Manager File Format

Use the radio buttons to choose how to format the bibliographic data you're harvesting. Several citation manager formats are available, including EndNote and BibTex.

Type of Import

If you have citation management software installed on your computer your Web browser should be able to import metadata directly into your reference database.

Direct Import: When the Direct Import option is selected (the default state), a dialogue box will give you the option to Save or Open the downloaded citation data. Choosing Open will either launch your citation manager or give you a choice of applications with which to use the metadata. The Save option saves the file locally for later use.

Indirect Import: When the Indirect Import option is selected, the metadata is displayed and may be copied and pasted as needed.

About This Article

© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Data & Comments

Data

Views
62
Downloads
18
Citations
0
Comments
0
3

Comments

Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at support@oaepublish.com.

0
Download PDF
Share This Article
Scan the QR code for reading!
See Updates
Contents
Figures
Related
Extracellular Vesicles and Circulating Nucleic Acids
ISSN 2767-6641 (Online)
Follow Us

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/